Coegin Pharma has, both under its own auspices and through long-term international cooperation, since the beginning of 2005 conducted extensive research and development of drug substances with a focus on inhibiting the key enzyme cPLA2α, which is part of the phospholipase A2 family.
The company's research and technology is based on the work that Professor Berit Johansen and her research group have conducted for three decades at the Norwegian University of Science and Technology.
Berit was the first to identify the unique properties of the cPLA2α enzyme.
The enzyme plays a central role in inflammation and uncontrolled cell growth and has received both preclinical and clinical thorough validation as a very promising therapeutic target for a number of inflammatory diseases, cancer and fibrosis. The company's operations are conducted cost-effectively through a semi-virtual organization with a mix of in-house research together with outsourced expertise at external CROs.
At the beginning of 2022, the merger acquisition of Follicum was completed. Coegin Pharma sees significant potential in Follicum's unique peptide technology and research in diabetes complications and there are opportunities for synergies with Coegin Pharma's research and development. The goal is to develop more clinical drug candidates with potential in indications with a great medical need. This will be done in close collaboration with the internationally recognized researchers, Professor Jan Nilsson and Professor Anna Hultgårdh from Lund University, who both had key roles in Follicum.